Search research articles
Contact Us
Filters
Showing results (41-50 of 102) with videos related to
Page
of 11
Sort By:
The Oncologist
|
September 22, 2020
Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies
Shehara Mendis, Seerat Anand, Joanna M Karasinska, et al.
Future Oncology (London, England)
|
December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
JCO Precision Oncology
|
January 20, 2022
International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i>-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel
Satoshi Fujii, Anthony M Magliocco, Jihun Kim, et al.
Clinical Colorectal Cancer
|
September 13, 2018
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics
Maliha Khan, Jonathan M Loree, Shailesh M Advani, et al.
Journal of the National Cancer Institute
|
January 19, 2018
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia
Michael J Overman, Renata Ferrarotto, Kanwal Raghav, et al.
Cancers
|
February 24, 2024
Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
Benny Johnson, Van Morris, Xuemei Wang, et al.
NPJ Precision Oncology
|
February 5, 2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, et al.
British Journal of Cancer
|
August 1, 2020
Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer
Kanwal Raghav, John P Shen, Alexandre A Jácome, et al.
Oncotarget
|
February 1, 2019
Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
Roberto Carmagnani Pestana, Manal M Hassan, Reham Abdel-Wahab, et al.
Journal of the National Cancer Institute
|
December 27, 2025
Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
Giulia Maddalena, Ymke van der Pol, Oscar E Villarreal, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 102) with videos related to
Sort By:
Page
of 11
The Oncologist
|
September 22, 2020
Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies
Shehara Mendis, Seerat Anand, Joanna M Karasinska, et al.
Future Oncology (London, England)
|
December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
JCO Precision Oncology
|
January 20, 2022
International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i>-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel
Satoshi Fujii, Anthony M Magliocco, Jihun Kim, et al.
Clinical Colorectal Cancer
|
September 13, 2018
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics
Maliha Khan, Jonathan M Loree, Shailesh M Advani, et al.
Journal of the National Cancer Institute
|
January 19, 2018
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia
Michael J Overman, Renata Ferrarotto, Kanwal Raghav, et al.
Cancers
|
February 24, 2024
Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
Benny Johnson, Van Morris, Xuemei Wang, et al.
NPJ Precision Oncology
|
February 5, 2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, et al.
British Journal of Cancer
|
August 1, 2020
Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer
Kanwal Raghav, John P Shen, Alexandre A Jácome, et al.
Oncotarget
|
February 1, 2019
Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
Roberto Carmagnani Pestana, Manal M Hassan, Reham Abdel-Wahab, et al.
Journal of the National Cancer Institute
|
December 27, 2025
Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
Giulia Maddalena, Ymke van der Pol, Oscar E Villarreal, et al.
Page
of 11